SCHEMBL7319701

SCHEMBL7319701

NCCc1cn(Cc2ccc(C(=O)O)o2)c2ccc(OCc3ccc(-c4ccccc4)cc3)cc12

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.61
IGF1R P08069 4/20 0.61
FLT4 P35916 4/20 0.61
KDR P35968 4/20 0.61
PLA2G2A P14555 4/20 0.48
LTA4H P09960 1/20 0.48
PPARD Q03181 3/20 0.47
LTB4R Q15722 3/20 0.47
LTB4R2 Q9NPC1 3/20 0.47
PPARG P37231 2/20 0.47
PPARA Q07869 2/20 0.47
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ICMT O60725 3/20 0.44
EDNRB P24530 1/20 0.42
EDNRA P25101 1/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7318362 0.95 EGFR (0.54) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7318750 0.91 EGFR (0.54) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7319697 0.89 EGFR (0.48) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7317740 0.89 EGFR (0.51) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7310884 0.88 EGFR (0.55) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7308485 0.88 EGFR (0.47) EGFRIGF1RFLT4KDRPPARD
SCHEMBL7312021 0.86 EGFR (0.69) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7317916 0.86 EGFR (0.47) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7306051 0.86 PPARG (0.54) EGFRIGF1RFLT4KDRPLA2G2A
SCHEMBL7319193 0.85 FFAR1 (0.47) EGFRIGF1RFLT4KDRPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US claimed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 WO claimed
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007877-A1 NOVEL ANTI-INFECTIVES CTSL, MMP8, SERPINB1 EGFR 4683/4885IGF1R 4834/4885FLT4 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.